கெநில்‌வர்த் புதியது News Today : Breaking News, Live Updates & Top Stories | Vimarsana

email article
Pharmacokinetic data indicated that an implant that elutes islatravir, an antiretroviral agent, could protect people at-risk of contracting HIV for at least a year, positioning it as a potential form of pre-exposure prophylaxis (PrEP), researchers reported.
In a trial in which people at low risk of HIV-infection were implanted with three different doses of islatravir, blood levels of islatravir remained well above the level considered sufficient for protection against infection at week 12, according to Randolph Matthews, MD, PhD, a senior scientist at Merck in Kenilworth New Jersey.
The largest dose – 56 mg – was projected to yield adequate islatravir blood levels for almost all individuals for at least 52 weeks, he said in his oral presentation at the virtual Conference on Retroviruses and Opportunistic Infections (CROI). ....

Randolph Matthews , Sharon Hillier , Richard Koup , University Of Pittsburgh School Medicine , National Institute Of Allergy , Kenilworth New , Opportunistic Infections , National Institute , Infectious Diseases , Pittsburgh School , Medpage Today , Human Immunodeficiency Virus Infection , Infectious Disease , Pruritic Disorders , ரேண்டால்ஃப் மேத்யூஸ் , ஷரோன் ஹில்லியர் , பல்கலைக்கழகம் ஆஃப் பிட்ஸ்பர்க் பள்ளி மருந்து , தேசிய நிறுவனம் ஆஃப் ஒவ்வாமை , கெநில்‌வர்த் புதியது , தேசிய நிறுவனம் , தொற்று நோய்கள் , பிட்ஸ்பர்க் பள்ளி , தொற்று நோய் ,